Nat Commun: Molecular signs of breast cancer in Asia reveal the specificity of the disease in the population

Breast cancer is a heterogeneous disease, which is generally guided by histological pathology and clinical demographic characteristics.
such as endocrine therapy in ER-plus (estrogen-positive) tumors, HER2 targeted therapy in Her2-plus tumors, and treatment of patients with poor prognosis through chemotherapy.
molecular features of breast tumors is conducive to the development of new therapies and suitable treatment options.
of other populations where genetic, lifestyle and environmental factors vary from previous studies (mainly among women of European descent).
, however, studies of non-white breast cancer patients lack details.
molecular subtype analysis of breast cancer patients in Malaysia In this study, the researchers analyzed the number of genetic mutations, transcriptions and copies in 560 malaysian breast tumor patients, and compared the incidence of breast cancer in Asian and white women.
researchers found that the prevalence of HER2-molecule subtypes increased in patients with ER-Asian breast cancer compared to white breast cancer patients, and the prevalence was higher in patients with TP53 cell mutations.
further study of tumor immuno-microencient analysis in breast cancer patients in Malaysia showed that the elevated immune scores of breast cancer patients in Asia indicated a potential clinical response to immunosuperative inhibitors.
HER2 subtype and higher immune scores were associated with improved survival rates in patients, while cell mutations carrying TP53 and ER-plus status corresponded to poor survival rates in patients.
, the findings reveal that differences in different populations provide insights into the understanding of breast cancer and provide a basis for precision medicine in different populations.
。